Treatment choice should reflect physiological reserve, bladder function and pathway delay.
Radical bladder radiotherapy should normally include a suitable concurrent radiosensitiser; if one regimen is unsuitable, consider another established option.
Chronological age can quietly become the treatment decision in muscle-invasive bladder cancer. An older patient may be directed towards radiotherapy before physiological reserve is measured. The result is a choice narrowed by assumption rather than a comparison of the two definitive options.
Radical cystectomy and bladder-preserving radical radiotherapy are both definitive treatments for non-metastatic disease. Available comparative data find no clear advantage for cystectomy, although randomised evidence remains limited. The findings cannot make the treatments interchangeable for every patient. They are sufficient to reject the idea that cystectomy is the only curative route.
Choosing cystectomy or bladder preservation
Physiological reserve, comorbidity, functional capacity and patient preference need to be recorded separately from age. Baseline urinary function also matters. Severe lower urinary tract symptoms may make bladder preservation less attractive because radiotherapy can worsen an already poorly functioning bladder.
Residual tumour after transurethral resection needs a separate judgement. Radical radiotherapy remains possible, particularly when another attempt at maximal resection would delay definitive treatment. Complete tumour clearance at resection should not become an automatic entry requirement for bladder preservation.
The radiotherapy pathway also needs to be described accurately. Radical bladder radiotherapy should normally include a suitable concurrent radiosensitiser. The options discussed include mitomycin C with fluorouracil, carbogen with nicotinamide and weekly gemcitabine. If one regimen is unsuitable, another established option may still be available.
Delay can undo an otherwise thoughtful decision. Referral, transurethral resection, oncology review, systemic treatment and definitive therapy may together extend beyond 100 days. Waiting for a final choice between surgery and radiotherapy before arranging oncology assessment adds avoidable time. Parallel review by a cystectomy-experienced urologist and a bladder-preservation clinical oncologist allows systemic therapy planning and informed discussion to proceed together.
A patient in their late seventies should reach this decision with physiological reserve measured, bladder function discussed and both definitive options explained. The service needs to make that possible without serial referrals consuming weeks. Treatment can then reflect the tumour, the patient’s fitness and the function they are trying to preserve.
Organ retrieval provides repeated, supervised exposure to rare live-tissue trauma manoeuvres, including thoracic aortic clamping and major vascular control. Speed comes from rehearsal, anatomical landmarks, role clarity and equipment readiness rather than hurried hand movements.
Irregular cycles, hyperandrogenic symptoms and metabolic dysfunction can occur at any body mass index. Diagnosis integrates clinical features while excluding mimics; management follows reproductive goals and requires long-term surveillance for metabolic, cardiovascular, psychological and endometrial complications.
Metabolomics, reverse phenotyping and pathway-proximal functional testing can help resolve uncertain inherited metabolic diagnoses. Other reports examine inflammation in fatty acid oxidation disorders, personalised weight-loss treatment in urea cycle disease and multifactorial hyperammonaemia after bariatric surgery.
Blood biomarkers may make assessment of Alzheimer’s disease-related changes more accessible and cost-effective in symptomatic patients. Current diagnostic use should remain separate from the future possibility of identifying people at risk before symptoms develop.
Muscle-invasive bladder cancer may be treated definitively with radical cystectomy or bladder-preserving radiotherapy. Selection should separate chronological age from physiological reserve, baseline urinary function and patient preference, while parallel specialist review limits avoidable delay.
When reviewing muscle-invasive bladder cancer, document physiological reserve, comorbidity and baseline urinary function separately from age. Arrange urology and clinical oncology assessment in parallel. Before radical radiotherapy, record the selected concurrent radiosensitiser and why it suits the patient.
An adult aged 79 years has non-metastatic muscle-invasive bladder cancer, cardiovascular disease, diabetes and limited exercise capacity. Radical cystectomy and bladder-preserving radiotherapy remain possible. Which assessment should carry the greatest weight when deciding whether major surgery is realistic?
A comprehensive assessment of physiological reserve, comorbidity and functional capacity. Chronological age alone should not determine surgical suitability.
During trauma laparotomy, an adult has a rapidly expanding zone 1 retroperitoneal haematoma above the transverse mesocolon. The haematoma may be tamponading injury to the supraceliac aorta or major visceral vessel origins. What should the surgeon establish before opening it?
Establish a plan for proximal and distal vascular control, using the supraceliac aorta as the relevant proximal target. Keep the contained haematoma closed until that control strategy is ready.
An adult with a normal body mass index has irregular periods, acne, hirsutism, raised free testosterone and reduced sex hormone-binding globulin. Alternative endocrine causes have been excluded. Which process most directly links the reproductive and androgenic features of polyendocrine metabolic ovarian syndrome?
Insulin resistance with chronic hyperinsulinaemia. This stimulates ovarian androgen production and reduces hepatic sex hormone-binding globulin, increasing free testosterone even at a normal body mass index.
.svg)